Teva Announces Approval Of Generic Breast Cancer, Osteoporosis Drug Evista Tablets In The US

Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the approval from the US Food and Drug Administration (FDA) to market the generic equivalent to Evista (Raloxifene) Tablets, 60 mg, in the United States.

Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Teva will begin shipping the product within the next 30 days.

Evista 60 mg Tablets marketed by Eli Lilly and Company, had annual sales of approximately $824 million in the United States, according to IMS data as of December 2013.


Read more about: , , , ,

Wordpress site Developed by Fixing WordPress Problems